Literature DB >> 8897926

Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat.

A Décarie1, P Raymond, N Gervais, R Couture, A Adam.   

Abstract

Among the different enzymes responsible for the metabolism of bradykinin (BK), three peptidases look relevant in vivo: kininase I (KI), which transforms BK into its active metabolite, [des-Arg9]BK; kininase II (KII); and neutral endopeptidase, which inactivate BK and [des-Arg9]BK. The in vitro incubation of BK and [des-Arg9]BK in the serum of four species with or without enalaprilat and the quantification of the immunoreactivity of both peptides at different time intervals allowed the measurement of the kinetic parameters characterizing their metabolic pathways. Highly sensitive chemiluminescent enzyme immunoassays were used to measure the residual concentrations of BK and [des-Arg9]BK. Half-life (t1/2) of BK showed significant difference among species: rats (10 +/- 1 s) = dogs (13 +/- 1 s) < rabbits (31 +/- 1 s) < humans (49 +/- 2 s). t1/2 values of [des-Arg9]BK were also species dependent: rats (96 +/- 6 s) < < rabbits (314 +/- 6 s) = dogs (323 +/- 11 s) = humans (325 +/- 12 s). Enalaprilat significantly prevented the rapid BK and [des-Arg9]BK degradation in all species except that of [des-Arg9]BK in rat serum. Relative amount of BK hydrolyzed by serum KII was given as follows: rabbits (93.7 +/- 14.8%) = rats (83.6 +/- 6.7%) = humans (76.0 +/- 7.5%) > dogs (50.0 +/- 3.9%). Its importance in the hydrolysis of [des-Arg9]BK was 5.2 +/- 0.5% in rats < < 33.9 +/- 1.5% in humans < 52.0 +/- 1.1% in rabbits < 65.1 +/- 3.4% in dogs. The participation of serum KI in the transformation of BK into [des-Arg9]BK was dogs (67.2 +/- 5.3%) > > humans (3.4 +/- 1.2%) = rabbits (1.8 +/- 0.2%) = rats (1.4 +/- 0.3%). Finally, no significant difference on t1/2 values for BK and [des-Arg9]BK could be demonstrated between serum and plasma treated with either sodium citrate or a thrombin inhibitor. These results revealed striking species differences in the serum metabolism of kinins that could address at least partially some of the controversial data related to the cardioprotective role of kinins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897926     DOI: 10.1152/ajpheart.1996.271.4.H1340

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  16 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

3.  Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats.

Authors:  F Cloutier; R Couture
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Non-competitive pharmacological antagonism at the rabbit B(1) receptor.

Authors:  J F Larrivée; L Gera; S Houle; J Bouthillier; D R Bachvarov; J M Stewart; F Marceau
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Expression, distribution and function of kinin B1 receptor in the rat diabetic retina.

Authors:  Soumaya Hachana; Menakshi Bhat; Jacques Sénécal; Frédéric Huppé-Gourgues; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2018-02-13       Impact factor: 8.739

6.  A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer.

Authors:  Wanyi Tai; Zhijin Chen; Ashutosh Barve; Zhonghua Peng; Kun Cheng
Journal:  Pharm Res       Date:  2013-09-26       Impact factor: 4.200

7.  Absence of ligand-induced regulation of kinin receptor expression in the rabbit.

Authors:  T Sabourin; K Guay; S Houle; J Bouthillier; D R Bachvarov; A Adam; F Marceau
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

8.  Pharmacologic and autoradiographic evidence for an up-regulation of kinin B(2) receptors in the spinal cord of spontaneously hypertensive rats.

Authors:  Frank Cloutier; Hudson de Sousa Buck; Brice Ongali; Réjean Couture
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

9.  Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P.

Authors:  Christian Drouet; Anik Désormeaux; Josée Robillard; Denise Ponard; Laurence Bouillet; Ludovic Martin; Gisèle Kanny; Denise-Anne Moneret-Vautrin; Jean-Luc Bosson; Jean-Louis Quesada; Margarita López-Trascasa; Albert Adam
Journal:  J Allergy Clin Immunol       Date:  2007-12-26       Impact factor: 10.793

10.  Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.

Authors:  R M Fryer; J Segreti; P N Banfor; D L Widomski; B J Backes; C W Lin; S J Ballaron; B F Cox; J M Trevillyan; G A Reinhart; T W von Geldern
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.